Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mochida And Ayumi Launch Unique Humira Biosimilar Formulation In Japan

Launch And NHI Listing Follows Approval In March This Year

Executive Summary

A new formulation of biosimilar Humira is now available in Japan, alongside three other presentations that join biosimilar products launched by partners Viatris and Fujifilm Kyowa Kirin Biologics at the start of this year.

You may also be interested in...



AbbVie Sees Solid Japan Outlook Despite 2020 Dip

AbbVie expects double-digit sales growth in Japan over the mid-term despite a decline last year, driven in large part by multi-indication plans for new products. 

Japan Approves First Humira Biosimilar

Japan has approved its first biosimilar rival to Humira. Mylan is set to market the Fujifilm Kyowa Kirin Biologics adalimumab biosimilar, having already launched the product as Hulio in Europe.

What’s Next? Five Things To Look Out For In October

A busy October will include planned biosimilar launches and key appointments for the off-patent sector.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151444

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel